Revolution Medicines Reports U.S. FDA Approves Its Rasonque
RVMD•U.S. FDA approves Rasonque for metastatic pancreatic cancer
- U.S. FDA approves Revolution Medicines’ Rasonque™ (daraxonrasib), the first broad RAS-targeted medicine in metastatic pancreatic cancer.
- Revolution Medicines says Rasonque 300 mg once-daily oral tablets are now available in the U.S.
